{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:39:30Z","timestamp":1790743170449,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04861-x","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:16:04Z","timestamp":1769069764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First-in-class HIF-2\u03b1 therapy in genitourinary oncology: Belzutifan from von Hippel\u2013Lindau disease to advanced renal cell carcinoma"],"prefix":"10.1007","volume":"96","author":[{"given":"Irem","family":"Karaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-0864","authenticated-orcid":false,"given":"Bulent","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"1","key":"4861_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11033-025-10403-8","volume":"52","author":"E Harbi","year":"2025","unstructured":"Harbi E, Aschner M (2025) Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Mol Biol Rep 52(1):281","journal-title":"Mol Biol Rep"},{"key":"4861_CR2","first-page":"298","volume":"128","author":"WG Kaelin","year":"2017","unstructured":"Kaelin WG (2017) Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc 128:298\u2013307","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"4861_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.tibs.2025.06.005","volume":"50","author":"K Acu\u00f1a-Pilarte","year":"2025","unstructured":"Acu\u00f1a-Pilarte K, Koh MY (2025) The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation. Trends Biochem Sci 50:677\u2013694","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"4861_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneph.2017.59","volume":"13","author":"HI Wettersten","year":"2017","unstructured":"Wettersten HI, Aboud OA, Lara PN et al (2017) Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol 13(7):410\u2013419","journal-title":"Nat Rev Nephrol"},{"issue":"18","key":"4861_CR5","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace EM, Rizzi JP, Han GA, Small-Molecule (2016) Antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76(18):5491\u20135500","journal-title":"Cancer Res"},{"issue":"5","key":"4861_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cmet.2018.07.020","volume":"28","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Bezwada D, Mashimo T (2018) Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab 28(5):793\u2013800e792","journal-title":"Cell Metab"},{"key":"4861_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS (2025) Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol 17:17588359251317846","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"4861_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","volume":"41","author":"A Palazon","year":"2014","unstructured":"Palazon A, Goldrath AW, Nizet V et al (2014) HIF transcription factors, inflammation, and immunity. Immunity 41(4):518\u2013528","journal-title":"Immunity"},{"issue":"10","key":"4861_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/s41401-021-00852-9","volume":"43","author":"J-j Zhuang","year":"2022","unstructured":"Zhuang J-j, Liu Q, Wu D-l et al (2022) Current strategies and progress for targeting the undruggable transcription factors. Acta Pharmacol Sin 43(10):2474\u20132481","journal-title":"Acta Pharmacol Sin"},{"key":"4861_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/molpharm.122.000525","volume":"102","author":"X Ren","year":"2022","unstructured":"Ren X, Diao X, Zhuang J, Wu D (2022) Structural basis for the allosteric inhibition of hypoxia-inducible factor-2 by belzutifan. Mol Pharmacol 102:240\u2013247","journal-title":"Mol Pharmacol"},{"key":"4861_CR11","first-page":"231","volume":"2","author":"AH Shaikat","year":"2025","unstructured":"Shaikat AH, Azad SMAK, Tamim MAR, Ullah MS, Amin MN, Sabbir MK (2025) Investigating hypoxia-inducible factor signaling in cancer: mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathog Ther 2:231\u2013245","journal-title":"Cancer Pathog Ther"},{"key":"4861_CR12","first-page":"1158","volume":"131","author":"SU Shah","year":"2024","unstructured":"Shah SU et al (2024) Oral Hypoxia-Inducible factor 2\u03b1 inhibitor Belzutifan in ocular von Hippel\u2013Lindau disease: subgroup analysis of LITESPARK-004. Ophthalmology 131:1158\u20131166","journal-title":"Ophthalmology"},{"issue":"10","key":"4861_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos O, Iversen AB, Narayan V et al (2024) Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 25(10):1325\u20131336","journal-title":"Lancet Oncol"},{"issue":"22","key":"4861_CR14","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","volume":"28","author":"M Hazarika","year":"2022","unstructured":"Hazarika M et al (2022) FDA approval summary: Belzutifan for von Hippel\u2013Lindau Disease\u2013Associated tumors. Clin Cancer Res 28(22):4843\u20134849","journal-title":"Clin Cancer Res"},{"key":"4861_CR15","doi-asserted-by":"publisher","first-page":"113434","DOI":"10.1016\/j.ejca.2023.113434","volume":"196","author":"E Jonasch","year":"2024","unstructured":"Jonasch E, Bauer TM, Papadopoulos KP et al (2024) Phase I LITESPARK-001 study of Belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer 196:113434","journal-title":"Eur J Cancer"},{"issue":"5","key":"4861_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, McDermott DF, Merchan J et al (2023) Belzutifan plus Cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol 24(5):553\u2013562","journal-title":"Lancet Oncol"},{"issue":"8","key":"4861_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K et al (2024) Belzutifan versus everolimus for advanced Renal-Cell carcinoma. N Engl J Med 391(8):710\u2013721","journal-title":"N Engl J Med"},{"key":"4861_CR18","doi-asserted-by":"publisher","first-page":"S1262","DOI":"10.1016\/j.annonc.2024.08.2317","volume":"35","author":"BI Rini","year":"2024","unstructured":"Rini BI, Suarez Rodriguez C, Albiges L et al (2024) LBA74 final analysis of the phase III LITESPARK-005 study of Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol 35:S1262\u2013S1263","journal-title":"Ann Oncol"},{"issue":"22","key":"4861_CR19","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","volume":"30","author":"J Fallah","year":"2024","unstructured":"Fallah J, Heiss BL, Joeng HK et al (2024) FDA approval summary: Belzutifan for patients with advanced renal cell carcinoma. Clin Cancer Res 30(22):5003\u20135008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4861_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","volume":"26","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Bauer TM, Merchan J et al (2025) Belzutifan plus Cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol 26(1):64\u201373","journal-title":"Lancet Onco"},{"issue":"3","key":"4861_CR21","doi-asserted-by":"publisher","first-page":"oyae276","DOI":"10.1093\/oncolo\/oyae276","volume":"30","author":"SH Choi","year":"2025","unstructured":"Choi SH, Chen Y-W, Panian J et al (2025) Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma. Oncologist 30(3):oyae276","journal-title":"Oncologist"},{"issue":"2","key":"4861_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/fon-2022-0802","volume":"19","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Schmidinger M, Eto M et al (2023) LITESPARK-011: Belzutifan plus lenvatinib vs Cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy. Future Oncol 19(2):113\u2013121","journal-title":"Future Oncol"},{"key":"4861_CR23","unstructured":"ClinicalTrials.gov (2025) NCT04736706 \u2014 Pembrolizumab\u2009+\u2009belzutifan\u2009+\u2009lenvatinib vs pembrolizumab\u2009+\u2009lenvatinib (LITESPARK-012)"},{"key":"4861_CR24","doi-asserted-by":"crossref","unstructured":"Qiu J, Zhou J, Cai L et al (2025) Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease\u2013associated tumors: results of LITESPARK-015 study. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2025.43.5_suppl.534"},{"key":"4861_CR25","unstructured":"Canal A (2025) FDA Updates Highlighting the Latest Cancer Treatments. Oncology Times"},{"key":"4861_CR26","unstructured":"A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma\/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2\u03b1 Related Genetic Alterations [Internet] (2021) Available from: https:\/\/clinicaltrials.gov\/study\/NCT04924075"},{"issue":"3","key":"4861_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.v12i3.413","volume":"12","author":"R Dogra","year":"2025","unstructured":"Dogra R, Vaishampayan U (2025) Hypoxia inducible Factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors. J Kidney Cancer VHL 12(3):1","journal-title":"J Kidney Cancer VHL"},{"key":"4861_CR28","doi-asserted-by":"crossref","unstructured":"Strowd RE, De La Fuente MI, Bauer TM et al (2024) Phase 1 LITESPARK-001 study of Belzutifan in advanced solid tumors: results of the glioblastoma cohort. American Society of Clinical Oncology","DOI":"10.1093\/noajnl\/vdaf242"},{"issue":"18","key":"4861_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2217\/fon-2023-0679","volume":"20","author":"L Curry","year":"2024","unstructured":"Curry L, Soleimani M (2024) Belzutifan: a novel therapeutic for the management of von Hippel\u2013Lindau disease and beyond. Future Oncol 20(18):1251\u20131266","journal-title":"Future Oncol"},{"issue":"5","key":"4861_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP (2021) Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27(5):802\u2013805","journal-title":"Nat Med"},{"key":"4861_CR31","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Plimack ER, Bauer TM (2020) Phase I\/II study of the oral HIF-2 \u03b1 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). American Society of Clinical Oncology","DOI":"10.1200\/JCO.2020.38.6_suppl.611"},{"issue":"1","key":"4861_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40360-024-00828-5","volume":"25","author":"G Song","year":"2024","unstructured":"Song G, Xue S, Zhu Y et al (2024) The efficacy and safety of Belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis. BMC Pharmacol Toxicol 25(1):100","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"4861_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.v12i3.413","volume":"12","author":"R Dogra","year":"2025","unstructured":"Dogra R, Vaishampayan U (2025) Hypoxia-Inducible Factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors. J Kidney Cancer VHL 12(3):1\u201315","journal-title":"J Kidney Cancer VHL"},{"issue":"15","key":"4861_CR34","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.3390\/ijms26157094","volume":"26","author":"J Kucharczyk","year":"2025","unstructured":"Kucharczyk J, Bhatt A, Bauer L et al (2025) Belzutifan-Associated hypoxia: A review of the novel Therapeutic, proposed mechanisms of Hypoxia, and management recommendations. Int J Mol Sci 26(15):7094","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4861_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","volume":"23","author":"X Yuan","year":"2024","unstructured":"Yuan X, Ruan W, Bobrow B et al (2024) Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discovery 23(3):175\u2013200","journal-title":"Nat Rev Drug Discovery"},{"key":"4861_CR36","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.ctrv.2024.102801","volume":"129","author":"P Rioja","year":"2024","unstructured":"Rioja P, Rey-Cardenas M, De Velasco G (2024) Targeting HIF-2\u03b1 and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma. Cancer Treat Rev 129:102801","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"4861_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Hirota K et al (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32(4):614\u2013621","journal-title":"Nat Genet"},{"issue":"10","key":"4861_CR38","doi-asserted-by":"publisher","first-page":"e230050","DOI":"10.1530\/ERC-23-0050","volume":"30","author":"JS Rosenblum","year":"2023","unstructured":"Rosenblum JS, Wang H, Nazari MA, Zhuang Z, Pacak K (2023) Pacak\u2013Zhuang syndrome: a model providing new insights into tumor syndromes. Endocr Relat Cancer 30(10):e230050","journal-title":"Endocr Relat Cancer"},{"issue":"22","key":"4861_CR39","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","volume":"385","author":"J Kamihara","year":"2021","unstructured":"Kamihara J, Hamilton KV, Pollard JA et al (2021) Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak\u2013Zhuang syndrome. N Engl J Med 385(22):2059\u20132065","journal-title":"N Engl J Med"},{"issue":"6","key":"4861_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/antiox13060659","volume":"13","author":"T Xie","year":"2024","unstructured":"Xie T, Yao L, Li X (2024) Advance in iron metabolism, oxidative stress and cellular dysfunction in experimental and human kidney diseases. Antioxidants 13(6):659","journal-title":"Antioxidants"},{"key":"4861_CR41","first-page":"171","volume":"2","author":"JJ Ban","year":"2014","unstructured":"Ban JJ, Ruthenborg RJ, Cho KW et al (2014) Regulation of obesity and insulin resistance by hypoxia-inducible factors. Hypoxia (Auckl) 2:171\u2013183","journal-title":"Hypoxia (Auckl)"},{"issue":"1","key":"4861_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","volume":"15","author":"FJ Gonzalez","year":"2018","unstructured":"Gonzalez FJ, Xie C, Jiang C (2018) The role of hypoxia-inducible factors in metabolic diseases. Nat Rev Endocrinol 15(1):21\u201332","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"4861_CR43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/bph.15696","volume":"179","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, Lu W, Yan H et al (2022) Established pulmonary hypertension in rats was reversed by a combination of a HIF-2\u03b1 antagonist and a p53 agonist. Br J Pharmacol 179(5):1065\u20131081","journal-title":"Br J Pharmacol"},{"issue":"11","key":"4861_CR44","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","volume":"198","author":"Z Dai","year":"2018","unstructured":"Dai Z, Zhu MM, Peng Y et al (2018) HIF\u20132\u03b1 inhibitor in pulmonary arterial hypertension models. Am J Respir Crit Care Med 198(11):1423\u20131434","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"4861_CR45","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","volume":"198","author":"Z Dai","year":"2018","unstructured":"Dai Z, Zhu MM, Peng Y (2018) Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2\u03b1 inhibitor. Am J Respir Crit Care Med 198(11):1423\u20131434","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4861_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41416-020-01107-w","volume":"124","author":"C Bernauer","year":"2021","unstructured":"Bernauer C, Man YS, Chisholm JC et al (2021) Hypoxia and its therapeutic possibilities in paediatric cancers. Br J Cancer 124(3):539\u2013551","journal-title":"Br J Cancer"},{"issue":"2","key":"4861_CR47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/0008-5472.CAN-20-2959","volume":"81","author":"MI Truica","year":"2021","unstructured":"Truica MI, Burns MC, Han H et al (2021) Turning up the heat on MYC: progress in Small-Molecule inhibitors. Cancer Res 81(2):248\u2013253","journal-title":"Cancer Res"},{"issue":"1","key":"4861_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/21541264.2024.2417475","volume":"16","author":"A McDermott","year":"2025","unstructured":"McDermott A, Tavassoli A (2025) Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery. Transcription 16(1):86\u2013117","journal-title":"Transcription"},{"issue":"4","key":"4861_CR49","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/ph17040494","volume":"17","author":"RK Rej","year":"2024","unstructured":"Rej RK, Allu SR, Roy J, Wang S (2024) Orally bioavailable Proteolysis-Targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs. Pharmaceuticals (Basel) 17(4):494","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"4861_CR50","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/cancers17101613","volume":"17","author":"N Bianchi","year":"2025","unstructured":"Bianchi N, Ancona P, Aguiari G (2025) Molecular mechanisms of drug resistance in clear cell renal cell carcinoma. Cancers (Basel) 17(10):1613","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4861_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney KD, Ma Y, Diaz de Leon A et al (2020) HIF-2 complex Dissociation, target Inhibition, and acquired resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in patients with clear cell renal cell carcinoma. Clin Cancer Res 26(4):793\u2013803","journal-title":"Clin Cancer Res"},{"key":"4861_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70075","author":"TK Schweickert","year":"2025","unstructured":"Schweickert PG, Piovesan D, Mitchell CG et al (2025) Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2\u03b1 dependent transcription. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.70075","journal-title":"Br J Pharmacol"},{"issue":"6suppl","key":"4861_CR53","doi-asserted-by":"publisher","first-page":"TPS748","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS748","volume":"41","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Bedke J, Karam JA et al (2023) Phase 3 LITESPARK-022: pembrolizumab (pembro) plus hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor Belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC). J Clin Oncol 41(6suppl):TPS748\u2013TPS748","journal-title":"J Clin Oncol"},{"issue":"10","key":"4861_CR54","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers11101607","volume":"11","author":"P Coliat","year":"2019","unstructured":"Coliat P, Ramolu L, J\u00e9gu J et al (2019) Constitutive or induced HIF-2 addiction is involved in resistance to anti-EGFR treatment and radiation therapy in HNSCC. Cancers (Basel) 11(10):1607","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4861_CR55","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1038\/s41467-020-20144-w","volume":"11","author":"RY Ebright","year":"2020","unstructured":"Ebright RY, Zachariah MA, Micalizzi DS et al (2020) HIF1A signaling selectively supports proliferation of breast cancer in the brain. Nat Commun 11(1):6311","journal-title":"Nat Commun"},{"issue":"4_suppl","key":"4861_CR56","doi-asserted-by":"publisher","first-page":"TPS669","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS669","volume":"40","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Van Cutsem E, Lee MS et al (2022) Phase 2 open-label study of pembrolizumab plus lenvatinib and Belzutifan in patients with advanced solid tumors. J Clin Oncol 40(4_suppl):TPS669","journal-title":"J Clin Oncol"},{"issue":"22","key":"4861_CR57","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 385(22):2036\u20132046","journal-title":"N Engl J Med"},{"issue":"6suppl","key":"4861_CR58","doi-asserted-by":"publisher","first-page":"TPS747","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS747","volume":"41","author":"DF McDermott","year":"2023","unstructured":"McDermott DF, Peer A, Agarwal N et al (2023) LITESPARK-024: A randomized phase 1\/2 study of Belzutifan with or without Palbociclib in patients with advanced renal cell carcinoma. J Clin Oncol 41(6suppl):TPS747\u2013TPS747","journal-title":"J Clin Oncol"},{"issue":"12","key":"4861_CR59","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2024.08.2338","volume":"35","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Brugarolas J, Ghatalia P et al (2024) Randomized phase II dose comparison LITESPARK-013 study of Belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol 35(12):1148\u20131156","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"4861_CR60","doi-asserted-by":"publisher","first-page":"TPS4594","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4594","volume":"39","author":"ER Plimack","year":"2021","unstructured":"Plimack ER, Hammers HJ, Choueiri TK et al (2021) Phase 1b\/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). J Clin Oncol 39(15_suppl):TPS4594","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04861-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:03:14Z","timestamp":1769072594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04861-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4861"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04861-x","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\/Ethics statement"}}],"article-number":"13"}}